BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Summary by AI BETAClose X

BioNTech announced that its exchange offer for CureVac shares has met its minimum condition, with 184,071,410 CureVac shares, representing approximately 81.74% of outstanding shares, tendered. The subsequent offering period has commenced and will conclude on December 18, 2025, allowing remaining CureVac shareholders to tender their shares. Following this, BioNTech will proceed with the post-offer reorganization, which may subject non-tendering shareholders to a 15% Dutch dividend withholding tax and could result in their shares ceasing to be tradable on national stock exchanges.

Disclaimer*

UK 100

Latest directors dealings